F-star Therapeutics Announces FDA Acceptance of IND Application for FS120
F-star’s first-in-class dual-agonist tetravalent bispecific antibody targeting CD137 and OX40 set to enter the clinic CAMBRIDGE, England & CAMBRIDGE, Mass.–(BUSINESS WIRE)– F-star Therapeutics Ltd., a...